The global market for blood-brain barrier (BBB) technology for therapeutics amounted to $12.3 million in 2010 and will reach $387 million by 2015, a compound annual growth rate (CAGR) of 99.3%.
SCOPE OF REPORT
The scope of this study encompasses companies that develop technologies to enable the crossing of the BBB and drug development in which a quality of the development is enabling the crossing of the BBB in cases in which passage was previously impossible often due to size. BCC analyzes each technology, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next 5 years. Technological issues, including the latest trends, are discussed.
ABOUT THE AUTHOR
Kim Lawson is a graduate of Mount Holyoke College with a degree in English Literature. She acquired experience as a healthcare journalist, including working for John Wiley & Sons for years as a print reporter, before serving as a research analyst in a small market research firm that focused on pharmaceuticals and biotechnology in the Research Triangle Park area of North Carolina. Before joining that firm, Kim published two reports on emerging and established diagnostics and therapeutics for benign and cancerous breast disease.